Ulrich Dauer
Director/Board Member bij Atriva Therapeutics GmbH
Vermogen: 22 490 $ op 31-03-2024
Profiel
Ulrich Dauer was the founder of 4SC AG, where he held the title of Chief Executive Officer from 1997 to 2013.
He is currently a Non-Executive Director at Atriva Therapeutics GmbH.
Dr. Dauer's former positions include Chief Executive Officer at OMEICOS Therapeutics GmbH and Ventaleon GmbH, and Chief Strategy Officer at Vectura GmbH.
He was also the Chief Executive & Financial Officer at Vivoryon Therapeutics NV from 2018 to 2021.
Dr. Dauer obtained a doctorate degree from Julius-Maximilians-Universität Würzburg.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-12-2022 | 38 563 ( 0.15% ) | 22 490 $ | 31-03-2024 |
Actieve functies van Ulrich Dauer
| Bedrijven | Functie | Begin |
|---|---|---|
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Director/Board Member | - |
Eerdere bekende functies van Ulrich Dauer
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Chief Executive Officer | 14-08-2023 |
| 4SC AG | Chief Executive Officer | 31-03-2013 |
Ventaleon GmbH
 Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Chief Executive Officer | - |
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Chief Executive Officer | - |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Corporate Officer/Principal | - |
Opleiding van Ulrich Dauer
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| 4SC AG | Health Technology |
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Health Technology |
